<DOC>
	<DOCNO>NCT01284062</DOCNO>
	<brief_summary>This study represent first investigation anrukinzumab patient active ulcerative colitis ( UC ) evaluate proof mechanism change mechanism base biomarker ( YKL 40 ) pharmacodynamic biomarkers ( fecal calprotectin , lactoferrin hs-CRP ) . It provide assessment safety , tolerability , pharmacokinetics ( PK ) administration multiple intravenous ( IV ) dose anrukinzumab .</brief_summary>
	<brief_title>Pharmacokinetics/Pharmacodynamics Biomarker Study Active Ulcerative Colitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Male Female , Age &gt; =18 &lt; =65 year Active ulcerative colitis ( UC ) beyond rectum base upon Mayo Score woman childbearing potential highly effective method contraception Indeterminate disease status , Crohn 's disease , ischemic colitis , positive HIV , positive history tuberculosis infection , active enteric infection , transplant organ recipient , concomitant steroid , immunosuppressive antiTNFs .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Active Ulcerative Colitis</keyword>
	<keyword>Phase 2A</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Randomized</keyword>
	<keyword>PK/PD Biomarker Study</keyword>
</DOC>